WuXi XDC Cayman Inc.

药明合联生物技术有限公司

02268.HK

Provides CRDMO services for antibody-drug conjugates (ADCs) and other bioconjugates, covering discovery, research, development and manufacturing for global biopharmaceutical companies. Ranked the second largest global ADC/bioconjugate CRDMO by 2022 revenue, per Frost & Sullivan.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Overseas markets and operations
• Business changes and acquisitions
• Backlog and project economics
• Capacity and utilisation
• Reliance on the controlling shareholder
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Investments and fair-value assets
• Non-IFRS measures and adjustments
• Non-recurring gains and losses
• Related-party transactions and balances